Est. 2001·3,000+ placements · six offices · four regions
M&A Activitycurated sourcedetected 2026-08-06 · confidence 95%

Last updated

Biogen: M&A Activity

Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.

Source: GNW — Mergers & Acquisitions

Who
Biogen · Biotech & Pharma · USA
What happened
Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.
When
2026-08-06
So what
Consolidation shifts the leadership question from growth to integration.

The leadership read

Consolidation shifts the leadership question from growth to integration. For Biogen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

Market context: Against a Talent Market Index of 95.4 (Cool) (down 5.3 month-on-month), Americas is at easing (-16.2pts) on signal share.

Biogen: 0 signals in the last 90 days — below the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Americas signal flow; 8 tracked across 92 days.

MitchelLake in this thematic

Also at Biogen →

More signals across Biotech & Pharma

M&A Activity · Americas

Repligen Corporation →

Repligen completed acquisition of BioLife Solutions for $11.25/share cash plus stock consideration. Transaction consolidates cell therapy bioprocessing capabilities and expands Repligen's product portfolio in high-growth cell and gene therapy market.

M&A Activity · Americas

Amgen →

Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.

M&A Activity · Americas

BioMarin Pharmaceutical Inc. →

BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.

M&A Activity · Americas

Teva Pharmaceuticals →

Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices

M&A Activity · Americas

Bristol Myers Squibb →

Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal

M&A Activity · Americas

Gilead Sciences →

Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio

Where this lands in our work

Weekly briefing

Track companies like Biogen — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record